Jaguar Health, Inc.

DB:1JA Stock Report

Market Cap: €10.6m

Jaguar Health Valuation

Is 1JA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1JA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1JA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1JA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1JA?

Key metric: As 1JA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1JA. This is calculated by dividing 1JA's market cap by their current revenue.
What is 1JA's PS Ratio?
PS Ratio1.2x
SalesUS$10.19m
Market CapUS$11.74m

Price to Sales Ratio vs Peers

How does 1JA's PS Ratio compare to its peers?

The above table shows the PS ratio for 1JA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.7x
B8FK Biofrontera
0.7xn/a€15.8m
SBX SynBiotic
7.2x39.7%€27.9m
0RX Redx Pharma
13.3x-37.6%€65.0m
HIGH Cantourage Group
29.5x38.6%€57.9m
1JA Jaguar Health
1.2x41.8%€11.7m

Price-To-Sales vs Peers: 1JA is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (14.1x).

Price to Sales Ratio vs Industry

How does 1JA's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

25 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
1JA Jaguar Health
 1.2x41.8%US$11.74m
1JA 1.2xIndustry Avg. 2.9xNo. of Companies33PS0612182430+
25 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.2%
1JA Jaguar Health
 1.2x25.6%US$11.74m
No more companies

Price-To-Sales vs Industry: 1JA is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Pharmaceuticals industry average (3.9x).

Price to Sales Ratio vs Fair Ratio

What is 1JA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1JA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio6.5x

Price-To-Sales vs Fair Ratio: 1JA is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

7D

2.0%

1Y

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

7D

5.0%

1Y

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

1.8%

1Y

-31.2%